0001209191-20-012195.txt : 20200224 0001209191-20-012195.hdr.sgml : 20200224 20200224183808 ACCESSION NUMBER: 0001209191-20-012195 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200224 FILED AS OF DATE: 20200224 DATE AS OF CHANGE: 20200224 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Domzalski David CENTRAL INDEX KEY: 0001727794 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36621 FILM NUMBER: 20646384 MAIL ADDRESS: STREET 1: C/O FOAMIX PHARMACEUTICALS LTD. STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001606645 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 BUSINESS PHONE: 97289316233 MAIL ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 FORMER COMPANY: FORMER CONFORMED NAME: Foamix Ltd. DATE OF NAME CHANGE: 20140428 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-24 0 0001606645 Foamix Pharmaceuticals Ltd. FOMX 0001727794 Domzalski David C/O FOAMIX PHARMACEUTICALS LTD. 2 HOLTZMAN STREET REHOVOT L3 7670402 ISRAEL 1 1 0 0 CEO Ordinary Shares 2020-02-24 4 A 0 103248 0.00 A 319323 D Options 4.03 2020-02-24 4 A 0 240912 0.00 A 2030-02-24 Ordinary Shares 240912 240912 D This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. The ordinary shares underlying this restricted share unit award vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024. Each option represents a contingent right to purchase one ordinary share of the issuer. The ordinary shares underlying these options vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024. /s/ Mutya Harsch as attorney-in-fact 2020-02-24